ArticleIJU case reports2025
Large-cell neuroendocrine carcinoma of the kidney effectively treated by nivolumab and ipilimumab.
Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neuroendocrine tumors originating in the kidney are rare, and standard treatments are not established. Case presentation: An 80-years-old man was referred to our hospital with renal dysfunction and a left renal mass. Based on CT and bone scintigraphy results, he was diagnosed as having a large left renal tumor with a thrombus in the inferior vena cava, harboring lymph node, liver, lung, and left iliac bone metastasis. The renal biopsy indicated a large-cell neuroendocrine carcinoma. Treatment with nivolumab + ipilimumab was introduced. The local and metastatic tumors had shrunk. Subsequently, treatment with nivolumab has remained effective for >2 years. Conclusion: This case demonstrates the efficacy of treatment with the immune-checkpoint inhibitors against large-cell neuroendocrine carcinoma of the kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.